Alopecia in Medical Technology
Navigation Links
Alopecia in Medical Technology
... occurred in relation to the hair loss."
alopecia Areata
An autoimmune form of hair loss that can affect men and women, alopecia areata, occurs when the body's white blood cells ... unpredictable from person to person. For example, alopecia areata can happen overnight or occur gradually ...
... LaserComb in the treatment of Androgenetic alopecia in males commonly known as 'male pattern ... the treatment of certain classes of Androgenetic alopecia in males. The adverse event profile was ... treatment for hair loss caused by Androgenic alopecia in males." About the HairMax LaserComb ...
... and rash (29% vs 12%) - In addition, 19% vs 52.3% reported alopecia (all grades) - Grade 3/4 hematologic ARs reported in >5% ... platelets/mm3, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%) ...
... and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. 0%), anemia (9.2% vs. 12.8%) and infection (6.9% vs. 6.1%). ... vs 8%), and grade 3/4 neutropenia (83% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients ...
... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
... adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, lymphopenia, stomatitis, leukopenia, alopecia and anemia. Study details: abstract #406 An open-label, multicenter Phase I trial evaluated daily RAD001 (2.5 mg, 5 mg and 10 mg) and ...
... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of ...
... events in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include ...
... headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
... are: flu-like symptoms, including headache, fatigue, aches and pains, fevers and chills; depression, nausea, loss of appetite and diarrhea; insomnia; alopecia (hair loss); a reaction at the site of injection; changes in blood liver function tests and in blood cell counts, including leukopenia (low white ...
... and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of ...
... was maintained through repeat cycles.(2) The most commonly reported all-cause adverse events by patients receiving casopitant included neutropenia, alopecia and fatigue, and were generally balanced across treatment arms.(2) About Casopitant Casopitant is an NK-1 receptor antagonist in Phase III ...
... safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase 1/2 trials it has induced tumor regressions and/or caused disease ...
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...
... The most common (>10%) non-hematologic adverse reactions (all grades) were nausea (27%), diarrhea (14%), vomiting (19%), fatigue (11%) and alopecia (10%).(2) About Small Cell Lung Cancer (SCLC)(3) SCLC is caused by an uncontrolled growth of cells beginning on the surface of the lung's breathing ...
... with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients in the PF group had more grade 3/4 thrombocytopenia (11% vs. 4%), stomatitis ...
... the CAELYX or the observation arm. The incidence of nausea/vomiting and alopecia were low and manageable; 21 percent of patients experienced grade 1 or 2 ... (a skin irritation, typically occurring on the hands and feet), rash, and alopecia (hair loss). About Schering-Plough Schering-Plough Corporation is a ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...
... and, at a median follow-up of 14.9 months, the median time to progression was 8.7 months and the overall survival was 16.8 months Neurotoxicity and alopecia were minimal and there were no cases of hand–foot syndrome reported in this study. Study author, Dr. Hamid Y. Sheikh of the Christie Hospital ...
... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine ...
... to 20% included: peripheral sensory neuropathy 60% (Grade 3/4: 14%); fatigue/asthenia 50% (Grade 3/4: 14%); myalgia/arthralgia 49% (Grade 3/4: 8%); alopecia 48% (Grade 3/4: 0%); nausea 42% (Grade 3/4: 2%); stomatitis/mucositis 29% (Grade 3/4: 7%); vomiting 29% (Grade 3/4: 1%); diarrhea 22% (Grade 3/4: ...
... LaserComb in the treatment of Androgenetic alopecia in males commonly known as 'male pattern ... the treatment of certain classes of Androgenetic alopecia in males. The adverse event profile was ... treatment for hair loss caused by Androgenic alopecia in males." About the HairMax LaserComb ...
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
... is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed. ... develop a drug that will become useful for the patients with androgenetic alopecia as soon as possible. Note: Androgenetic alopecia: Due to the ...... and rash (29% vs 12%) - In addition, 19% vs 52.3% reported alopecia (all grades) - Grade 3/4 hematologic ARs reported in >5% ... platelets/mm3, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%) ...
... and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. 0%), anemia (9.2% vs. 12.8%) and infection (6.9% vs. 6.1%). ... vs 8%), and grade 3/4 neutropenia (83% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients ...
... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
... risks and allowing for the treatment of both males and females. In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar ...... adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, lymphopenia, stomatitis, leukopenia, alopecia and anemia. Study details: abstract #406 An open-label, multicenter Phase I trial evaluated daily RAD001 (2.5 mg, 5 mg and 10 mg) and ...
... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of ...
... events in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include ...
... headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...
... are: flu-like symptoms, including headache, fatigue, aches and pains, fevers and chills; depression, nausea, loss of appetite and diarrhea; insomnia; alopecia (hair loss); a reaction at the site of injection; changes in blood liver function tests and in blood cell counts, including leukopenia (low white ...
... and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of ...
... was maintained through repeat cycles.(2) The most commonly reported all-cause adverse events by patients receiving casopitant included neutropenia, alopecia and fatigue, and were generally balanced across treatment arms.(2) About Casopitant Casopitant is an NK-1 receptor antagonist in Phase III ...
PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...Roche responds to announcement of 'IDEAL' hepatitis C trial results
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
... Non-hematologic adverse events included stomatitis (10/27 patients), skin rash (10/27), diarrhea (9/27), nausea (7/27), vomiting (5/27) and alopecia (2/27). The study has shown that CPX-351 is capable of inducing marrow aplasia with few severe non-hematologic adverse events. "CPX-351 is a ...... safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase 1/2 trials it has induced tumor regressions and/or caused disease ...
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...
... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...
... The most common (>10%) non-hematologic adverse reactions (all grades) were nausea (27%), diarrhea (14%), vomiting (19%), fatigue (11%) and alopecia (10%).(2) About Small Cell Lung Cancer (SCLC)(3) SCLC is caused by an uncontrolled growth of cells beginning on the surface of the lung's breathing ...
... with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients in the PF group had more grade 3/4 thrombocytopenia (11% vs. 4%), stomatitis ...
Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
... of patients with MBC were neutropenia (48%); alopecia (18%); leukopenia (11%); anemia (7%); fatigue ... (6%); creatinine elevation (5%); alopecia (1%-13%); and dyspnea (1%-7%). The most common ... events (all grades) were RBC transfusion (38%), alopecia (49%), neuropathy/sensory (29%), nausea (69%), ...... the CAELYX or the observation arm. The incidence of nausea/vomiting and alopecia were low and manageable; 21 percent of patients experienced grade 1 or 2 ... (a skin irritation, typically occurring on the hands and feet), rash, and alopecia (hair loss). About Schering-Plough Schering-Plough Corporation is a ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...
... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...
... and, at a median follow-up of 14.9 months, the median time to progression was 8.7 months and the overall survival was 16.8 months Neurotoxicity and alopecia were minimal and there were no cases of hand–foot syndrome reported in this study. Study author, Dr. Hamid Y. Sheikh of the Christie Hospital ...
... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine ...
... to 20% included: peripheral sensory neuropathy 60% (Grade 3/4: 14%); fatigue/asthenia 50% (Grade 3/4: 14%); myalgia/arthralgia 49% (Grade 3/4: 8%); alopecia 48% (Grade 3/4: 0%); nausea 42% (Grade 3/4: 2%); stomatitis/mucositis 29% (Grade 3/4: 7%); vomiting 29% (Grade 3/4: 1%); diarrhea 22% (Grade 3/4: ...
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
... through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients. "Ifosfamide ...Other ContentspalenesspalliativepalliativepalpitationpalpationpseudocystpandemicpandemicpandemicpandemicpandemicpanaceapanaceaOther TagsRecurrenceEcstasyWinningDetectingDetectingDetectingIncidence
(Date:11/24/2009)...protein that may help gut bacteria bind to the gas...probiotic producers to identify strains that are l...ics need to interact with cells lining the gut to ...rfaces in the gut they are more likely to stick ar... Nathalie Juge from the Institute of Food Research...
(Date:11/24/2009)...ber 24, 2009) -- The Wildlife Conservation Society... last remaining population of Siberian tigers has ...de of poaching and habitat loss. , W...als of what needs to be done to protect remaining ... The report was released by the Siberian Tig...
(Date:11/24/2009)...Spanish . , The presence of increased body f...bstances in the blood, hinders the loss and mainte...ct of the University of Navarra conducted by Estba...Pharmacy. , The project, entitled "A nutrigeneti...l of body weight and inflammation," examines how t...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2It can be predicted the reaction obese patients will have to a diet 2Antipsychotic Drugs Spur Dramatic Weight Gain in Kids 60185 1Antipsychotic Drugs Spur Dramatic Weight Gain in Kids 60185 2Antipsychotic Drugs Spur Dramatic Weight Gain in Kids 60185 3Antipsychotic Drugs Spur Dramatic Weight Gain in Kids 60185 4More Swine Flu Vaccine Coming Soon 60183 1More Swine Flu Vaccine Coming Soon 60183 2More Swine Flu Vaccine Coming Soon 60183 3Phone Counseling for Depression Rings With Promise 60181 1Phone Counseling for Depression Rings With Promise 60181 2(Date:11/30/2009)...TING, Pa., Nov. 30 The University ... it has signed an agreement with ECRI Institute... medical center members special pricing on ECRI,s ...ment will offer UHC members current data to assist...nt nonprofit organization, is a leader in providin...
(Date:11/30/2009)...age in high levels of physical activity may be unk...ing their risk for osteoarthritis, according to a ... Radiological Society of North America (RSNA). , ...l activity levels may be at greater risk for devel... for developing osteoarthritis," said Christoph St...
(Date:11/30/2009)...venient technique that, when added to breast ultra...from benign results, according to an ongoing study...ological Society of North America (RSNA). , When...s often use ultrasound to obtain additional inform...sult in more biopsies because of its relatively lo...
(Date:11/29/2009)...based Service Delivery Center one of EU,s Investme... Brno, Czech Republic (PRWEB) -- Moravia Worldwide...eased to announce its participation in the 5th EU-... China, on November 30, 2009. Moravia Worldwide is...ve established and grown a presence in Nanjing, th...
(Date:11/29/2009)...ors-in-training how to do ultrasound-guided proced...ithout compromising patient care and safety, accor...The study shows that this simulation-based trainin... residents, knowledge, dexterity and confidence fo...ided procedures, including breast biopsies, liver ...
Breaking Medicine News(10 mins):Health News:University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services 2Health News:University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services 3Health News:Too much physical activity may lead to arthritis 2Health News:Elastography reduces unnecessary breast biopsies 2Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2[0] University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services[0] Too much physical activity may lead to arthritis[0] Elastography reduces unnecessary breast biopsies[1] Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China [1] Simulated training for ultrasound-guided procedures improves safety without risk to patients
RecurrenceEcstasyPlutoniumRadiologistsWinningElasticityDetectingSteepComplexityFragmentationIncidenceHalvingMicrocapsulesStormy
Other Tagslifespan 2lifespan 3lifespan 4solve 2solve 3solve 4solve 5solve 6solve 7solve 8calculate 2controversy 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |